Xembify Now Available for Primary Humoral Immunodeficiency

Xembify (immune globulin subcutaneous, human- klhw), a 20% immune globulin solution has been made available by Grifols.

Xembify is indicated for the treatment of primary humoral immunodeficiency in patients 2 years of age and older. This includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.‎ 

Before switching to Xembify, serum IgG trough levels should be obtained to guide subsequent dose adjustments. When switching from intravenous immune globulin (IVIG), treatment with Xembify should begin 1 week after the patient’s last IVIG infusion. If switching to Xembify from another subcutaneous immune globulin (IGSC), the same weekly dose (in grams) should be administered as the weekly dose of prior IGSC treatment (in grams).

The product is supplied as a 0.2g/mL protein solution for subcutaneous infusion in 1g, 2g, 4g, and 10g single-use vials. It is available to patients and healthcare professionals through the following providers: Advanced InfusionCare, Nufactor a specialty infusion company, CVS/Specialty, Optum Infusion Services, and Accredo.

For more information visit grifols.com.